Mentari Therapeutics' Total Liabilities Rise to $78.61 Million From $10.26 Million at Year-EndPUBT·Nov 16, 2026 at 12:12 PMMTRI+6.83%
This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Fridaybenzinga_article·Nov 13, 2026 at 09:21 PMADI-3.72%DNLI-3.52%
Wedbush initiates coverage of Mentari Therapeutics at Outperform, sets price target at $33TradingView·Nov 13, 2026 at 01:34 PMMTRI+6.83%
Mentari Therapeutics Files Initial Beneficial Ownership Statement for Director Julianne BrunoPUBT·Nov 12, 2026 at 09:01 PMMTRI+6.83%
Analysts Cut Nvidia, Maintain Apple and CoreWeave Ratings, Upgrade Unilever, and Initiate Corning and Teradyne CoverageCoinLive·Nov 11, 2026 at 01:36 PMCDNA-5.34%CGNX-3.62%
Mentari Therapeutics Publishes Pro Forma Combined Financial Statements With InMed PharmaceuticalsPUBT·Nov 10, 2026 at 09:56 PMINM0.00%MTRI+6.83%
Mentari Therapeutics falls 19% on reverse split and name changeMarket Movers·Nov 10, 2026 at 05:58 PMMTRI+6.83%
Jefferies initiates coverage of Mentari Therapeutics at Buy, sets price target at $30TradingView·Nov 10, 2026 at 02:25 PMMTRI+6.83%
This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesdaybenzinga_article·Nov 10, 2026 at 01:31 PMFIX-4.93%MDB-5.17%
ADAR1 Capital Management reports acquisition of $34,571.592 in Mentari Therapeutics common sharesPUBT·Nov 10, 2026 at 01:19 AMMTRI+6.83%
Mentari Therapeutics Presents Migraine Drug Pipeline, Targets First Clinical Data in 2027PUBT·Nov 9, 2026 at 03:32 PMMTRI+6.83%